Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Communication
  • Published:

Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood

Gene Therapy volume 21, pages 440–443 (2014)Cite this article

Subjects

Abstract

Intravenous (i.v.) delivery of therapeutic viruses to human patients exposes virus particles to the potentially neutralising environment of the human bloodstream, where many components of the innate and adaptive immune system provide a formidable barrier to virus infection of target cells. Here we assess the haemocompatibility of ColoAd1, an oncolytic adenovirus currently undergoing clinical assessment for treatment of disseminated cancer by i.v. delivery. Compared with the commonly used serotype Ad5, ColoAd1 (which has a capsid derived from Ad11p) showed only minor inhibition of oncolytic activity by pooled human serum or washed human blood cells, with the amount of ColoAd1 required to kill cancer cells in vitro (the IC50) increasing <10-fold. However, some virus–blood interactions are concentration- and context-dependent, requiring study in whole, undiluted, human blood. ColoAd1 showed <50-fold increases in the IC50 in whole blood from most donors, whereas the activity of Ad5 was ablated. Extrapolating these findings to the clinical situation indicates that ColoAd1 would ‘breakthrough’ neutralisation in some patients receiving as few as 1010 ColoAd1 particles i.v., and in most patients receiving doses of 1012 or above, well within the achievable dose range.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Nemunaitis J, Cunningham C, Buchanan A, Blackburn A, Edelman G, Maples P et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 2001; 8: 746–759.

    Article  CAS  Google Scholar 

  2. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011; 477: 99–102.

    Article  CAS  Google Scholar 

  3. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S . Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010; 17: 718–730.

    Article  Google Scholar 

  4. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nature medicine 2013; 19: 329–336.

    Article  CAS  Google Scholar 

  5. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879–885.

    Article  CAS  Google Scholar 

  6. Sampath P, Li J, Hou W, Chen H, Bartlett DL, Thorne SH . Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects. Mol Ther 2013; 21: 620–628.

    Article  CAS  Google Scholar 

  7. Carlisle RC, Di Y, Cerny AM, Sonnen AF, Sim RB, Green NK et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood 2009; 113: 1909–1918.

    Article  CAS  Google Scholar 

  8. Kalyuzhniy O, Di Paolo N, Silvestry M, Hofherr S, Barry M, Stewart P et al. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci 2008; 105: 5483–5488.

    Article  CAS  Google Scholar 

  9. Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008; 132: 397–409.

    Article  CAS  Google Scholar 

  10. Xu Z, Qiu Q, Tian J, Smith JS, Conenello GM, Morita T et al. Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat Med 2013; 19: 452–457.

    Article  CAS  Google Scholar 

  11. Kuhn I, Harden P, Bauzon M, Chartier C, Nye J, Thorne S et al. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One 2008; 3: e2409.

    Article  Google Scholar 

  12. Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Bethune MP et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003; 77: 8263–8271.

    Article  CAS  Google Scholar 

  13. Lyons M, Onion D, Green NK, Aslan K, Rajaratnam R, Bazan-Peregrino M et al. Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol Ther 2006; 14: 118–128.

    Article  CAS  Google Scholar 

  14. Stone D, Ni S, Li Z-Y, Gaggar A, DiPaolo N, Feng Q et al. Development and assessment of human adenovirus type 11 as a gene transfer vector. J Virol 2005; 79: 5090–5104.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Funding was provided by Cancer Research UK.

Author information

Authors and Affiliations

  1. Department of Oncology, ORCRB, Roosevelt Drive, University of Oxford, Oxford, UK

    Y Di, L Seymour & K Fisher

Authors
  1. Y Di
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Seymour
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Fisher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K Fisher.

Ethics declarations

Competing interests

Leonard Seymour and Kerry Fisher hold equity in PsiOxus Therapeutics Ltd which is developing ColoAd1 as an oncolytic virus.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Di, Y., Seymour, L. & Fisher, K. Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood. Gene Ther 21, 440–443 (2014). https://doi.org/10.1038/gt.2014.2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/gt.2014.2

Keywords

This article is cited by

Search

Advanced search

Quick links